These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 34748290)
1. Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma". Mungmungpuntipantip R; Wiwanitkit V J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e28. PubMed ID: 34748290 [No Abstract] [Full Text] [Related]
2. Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma". Takahashi D; Mizuno T; Ebata T J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):e29. PubMed ID: 34748277 [No Abstract] [Full Text] [Related]
3. Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis. Takahashi D; Mizuno T; Yokoyama Y; Igami T; Yamaguchi J; Onoe S; Watanabe N; Maeda O; Ando M; Ebata T J Hepatobiliary Pancreat Sci; 2021 Sep; 28(9):716-726. PubMed ID: 34087061 [TBL] [Abstract][Full Text] [Related]
4. Complete response of recurrent perihilar cholangiocarcinoma following sintilimab combined with lenvatinib plus S-1: a case report and review of literature. Liu QQ; Yu XH; Tang QB; Chen D; Zhang R; Liu C; Shi XD Anticancer Drugs; 2024 Jan; 35(1):81-85. PubMed ID: 37227031 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. Belkouz A; Nooijen LE; Riady H; Franken LC; van Oijen MGH; Punt CJA; Erdmann JI; Klümpen HJ Cancer Treat Rev; 2020 Dec; 91():102110. PubMed ID: 33075684 [TBL] [Abstract][Full Text] [Related]
6. Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. Jeong H; Yoo C; Hepatology; 2023 Oct; 78(4):E74-E75. PubMed ID: 37459559 [No Abstract] [Full Text] [Related]
7. Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial. Hu YF; Gu HF; Jin YW; Li FY Hepatology; 2023 Oct; 78(4):E72-E73. PubMed ID: 37459557 [No Abstract] [Full Text] [Related]
8. [Long-Term Survival after Surgery with Postoperative Chemotherapy for Perihilar Cholangiocarcinoma with Residual Invasive Carcinoma at Ductal Resection Margins-A Case Report]. Oiwa T; Miura K; Sakata J; Yuza K; Toge K; Hirose Y; Takizawa K; Ichikawa H; Hanyu T; Nakano M; Nagahashi M; Shimada Y; Ishikawa T; Kobayashi T; Wakai T Gan To Kagaku Ryoho; 2020 Dec; 47(13):1899-1901. PubMed ID: 33468866 [TBL] [Abstract][Full Text] [Related]
9. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma. Kim SH; Kim IH; Kim SW; Lee SO World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621 [TBL] [Abstract][Full Text] [Related]
10. [Klatskin tumor - a case report]. Iwaniec-Karlikowska E; Augustyn M; Grys I Pol Merkur Lekarski; 2016 Feb; 40(236):107-9. PubMed ID: 27000815 [TBL] [Abstract][Full Text] [Related]
12. [A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy]. Tamura T; Mizuyama Y; Shinto O; Nishihara T; Nakagawa H; Ono Y Gan To Kagaku Ryoho; 2010 Nov; 37(12):2732-4. PubMed ID: 21224695 [TBL] [Abstract][Full Text] [Related]
13. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289 [TBL] [Abstract][Full Text] [Related]
14. Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma. Crouzet L; Edeline J; Le Du F; Boucher E; Audrain O; Raoul JL Acta Oncol; 2012 May; 51(5):687-8. PubMed ID: 22356625 [No Abstract] [Full Text] [Related]
15. No-Touch Concept Is Invalid for Left-Dominant Perihilar Cholangiocarcinoma. Ji G; Wang K; Li X J Gastrointest Surg; 2018 Mar; 22(3):558-559. PubMed ID: 29340919 [No Abstract] [Full Text] [Related]
16. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor. Takenaka M; Akiba J; Kawaguchi T; Niizeki T; Arinaga-Hino T; Sata M; Nakashima O; Yano H; Kage M Pathol Int; 2013 Apr; 63(4):233-5. PubMed ID: 23692426 [No Abstract] [Full Text] [Related]
17. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy]. Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995 [TBL] [Abstract][Full Text] [Related]
18. [Interdisciplinary diagnosis of and therapy for cholangiocarcinoma]. Kolligs FT; Zech CJ; Schönberg SO; Schirra J; Thasler W; Graeb C; Beuers U; Wilkowski R; Jacobs T; Böck S; Berster J; Heinemann V; Schäfer C Z Gastroenterol; 2008 Jan; 46(1):58-68. PubMed ID: 18188818 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. Gürlevik E; Fleischmann-Mundt B; Armbrecht N; Longerich T; Woller N; Kloos A; Hoffmann D; Schambach A; Wirth TC; Manns MP; Zender L; Kubicka S; Kühnel F Hepatology; 2013 Sep; 58(3):1031-41. PubMed ID: 23686746 [TBL] [Abstract][Full Text] [Related]
20. Development of Brugada syndrome following photodynamic therapy in a patient with cholangiocarcinoma. Bang DW; Hyon MS; Cho YD; Kim SK; Kwon YJ Korean J Intern Med; 2012 Mar; 27(1):95-7. PubMed ID: 22403506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]